Methicillin-resistant Staphylococcus aureus (MRSA) associated infection has become a worrisome issue worldwide. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several reports have highlighted the limitations of vancomycin. Daptomycin is successfully used for the treatment of serious MRSA infections, however selection of resistant strains has been reported during daptomycin-monotherapy. This review will briefly discuss the available data on daptomycin/beta-lactam combination therapies for the treatment of MRSA infections.